Get started
Author

Ursula Hasler-Strub

Observed names: Hasler-Strub, Ursula, U Hasler-Strub, U HaslerStrub, U. Hasler-Strub, Ursula Strub Ursula
Observed institutions: University of Bern, Kantonsspital St. Gallen, Universitair Ziekenhuis Leuven, University Hospital of Bern, Centre Hospitalier Universitaire Vaudois, Ente Ospedaliero Cantonale, Spital STS, Kantonsspital Winterthur, University Hospital Zurich, Engeriedspital, Cancer Trials Ireland, Hirslanden Klinik Aarau, University Hospital of Geneva, Hôpital de Morges, Luzerner Kantonsspital, Kantonsspital Baden, Solti, St. Claraspital, Lindenhofspital, Swiss Group For Clinical Cancer Research, Kantonsspital Graubünden, International Breast Cancer Study Group, Kantonsspital Aarau
ORCID: 0000-0002-2500-5882
Observed ORCID: 0000-0002-2500-5882
OpenAlex ID: A5035838287
Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis
1997 · B. Hess, U. Hasler-Strub, et al. · Nephrology Dialysis Transplantation · 93
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer
2023 · Christoph Mamot, Andreas Wicki, et al. · Scientific Reports · 56
PDF
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
2015 · Khalil Zaman, Ralph Winterhalder, et al. · European Journal of Cancer · 55
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
2016 · Christoph Rochlitz, Martin Bigler, et al. · BMC Cancer · 49
PDF
Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).
2023 · Florence Joly, Isabelle Laure Ray-Coquard, et al. · Journal of Clinical Oncology · 22
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial
2017 · A. Gennari, Z. Sun, et al. · Annals of Oncology · 18
PDF
185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial
2023 · H.S. Rugo, W. Jacot, et al. · ESMO Open · 16
PDF
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.
2014 · Christoph Rochlitz, Roger von Moos, et al. · Journal of Clinical Oncology · 14
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)
2025 · L. Malorni, S. Tyekucheva, et al. · Annals of Oncology · 11
Metabolic Evaluation of Patients With Recurrent Idiopathic Calcium Nephrolithiasis
1998 · B. Hess, U. Hasler-Strub, et al. · The Journal of Urology · 9
268P Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple-negative, EGFR positive breast cancer: A multicenter single arm phase II trial [SAKK 24/14]
2021 · A. Wicki, C. Mamot, et al. · Annals of Oncology · 6
Abstract RF1-02: Palbociclib plus letrozole versus weekly paclitaxel, both in combination w/ trastuzumab plus pertuzumab, as neoadjuvant treatment for patients w/ HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)
2025 · Luca Malorni, S. Tyekucheva, et al. · Clinical Cancer Research · 3
Abstract P1-18-01: Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE)
2019 · A Müller, AJ Templeton, et al. · Cancer Research · 3
Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]
2022 · Ursula Hasler-Strub, Andreas Mueller, et al. · Journal of Geriatric Oncology · 2
PDF
From New Molecular Insights to New Treatment Options in Endometrial Cancer
2022 · Ursula Hasler-Strub · healthbook TIMES Oncology Hematology · 2
PDF
Folate Receptor α: A New Target for an Old Enemy?
2020 · Katharina Ruf, Ursula Hasler-Strub · healthbook TIMES Oncology Hematology · 2
PDF
Abstract P5-15-05: Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the SNAP study
2017 · A Gennari, Z Sun, et al. · Cancer Research · 2
Abstract P1-10-06: Health economic evaluation of: Bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced breast cancer: A multicenter, randomized phase III trial - SAKK 24/0
2015 · Klazien W Matter-Walstra, Martin Bigler, et al. · Cancer Research · 2
Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial
2026 · Domenica Lorusso, Jérôme Martin-Babau, et al. · The Lancet · 1
Decision-Making in Intrathecal Therapy for Leptomeningeal Disease
2026 · Susanne Weindler, Thomas Hundsberger, et al. · Oncology · 1
DOMENICA study (GINECO-EN105b/ENGOT-en13): randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting (APGOT-EN1)
2024 · Chel Hun Choi, Isabelle Ray-Coquard, et al. · Annual Meeting of Korean Society of Gynecologic Oncology · 1
PDF
2104P Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
2023 · K. Johnson, B. Stoffel, et al. · Annals of Oncology · 1
PDF
Use of First-Line PARP Inhibitors in Ovarian Cancer
2019 · Ursula Hasler-Strub · healthbook TIMES Oncology Hematology · 1
Patient Selection for Partial Breast Irradiation in the Era of Sentinel Lymph Node Biopsy Omission: A Narrative Review
2026 · Efstratios Karagiannis, Roger von Moos, et al. · Cancers
Clinical Impact of Polygenic Risk Score Integration into CanRisk in Women with Familial Breast Cancer Risk and Negative Germline Testing: A Prospective Multicenter Study (PRoScreen)
2026 · Tobias Bethge, Riniker Salome, et al. · SSRN Electronic Journal
Works count: 38
Citation count: 370
H-index: 9
I10-index: 9
Year
Topic
Type